Treatment of pulmonary arterial hypertension in children;Traitement de l'hypertension artérielle pulmonaire de l'enfant

Archives de Pediatrie

Volumn 11, Issue 8, 2004, Pages 945-950

  Fraisse, A ^a   Habib, G ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

Child; Hypertension art rielle pulmonaire; Hypertension, pulmonary; Lung transplantation; Transplantation pulmonaire; Vasodilatateurs; Vasodilator agents

Indexed keywords

ANTIHYPERTENSIVE AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE IV INHIBITOR; PROSTACYCLIN; SILDENAFIL; VASODILATOR AGENT;

CATHETER; DRUG EFFECT; HEART ATRIUM SEPTUM; HUMAN; LUNG TRANSPLANTATION; PEDIATRICS; PULMONARY HYPERTENSION; REVIEW; SEPTOSTOMY; SIDE EFFECT; SURGICAL TECHNIQUE; TREATMENT OUTCOME; VASCULAR SURGERY;

EID: 3543136655     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcped.2004.01.026     Document Type: Short Survey

References (42)

1. Galiè N., Manes A., Uguccioni L., Serafini F., De Rosa M., Branzi A., et al. Primary pulmonary hypertension. Insights into pathogenesis from epidemiology. Chest. 114:1998;184S-194S
2. Barst R.J. Diagnosis and assessment of pulmonary hypertension in infants and children. Prog Pediatr Cardiol. 12:2001;279-288
3. Sandoval J., Bauerle O., Gomez A., Palomar A., Martinez Guerra M.L., Furuya M.E. Primary pulmonary hypertension in children: Clinical characterization and survival. J Am Coll Cardiol. 25:1995;466-474
4. Sanchez O., Humbert M., Sitbon O., Nunes H., Garcia G., Simoneau G. Hypertension artérielle pulmonaire associée aux connectivites. Rev Med Int. 23:2002;41-54
5. Speich R., Jenni R., Opravil M., Pfab M., Russi E.W. Primary pulmonary hypertension in HIV infection. Chest. 100:1991;1268-1271
6. Abenhaim L., Moride Y., Brenot F., Rich S., Benichou J., Kurz X., et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med. 335:1996;609-616
7. Krowka M.J. Hepatopulmonary syndrome versus portopulmonary hypertension: distinctions and dilemmas. Hepatology. 25:1997;1282-1284
8. Hopkins W.E., Waggoner A.D. Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome. Am J Cardiol. 89:2002;34-38
9. Garofano R.P., Barst R.J. Exercice testing in children with primary pulmonary hypertension. Pediatr Cardiol. 20:1999;61-64
10. Barst R.J., Maislin G., Fishman A.P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 99:1999;1197-1208
11. Sitbon O., Humbert M., Nunes H., Parent F., Garcia G., Hervé P., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 40:2002;780-788
12. Barst R.J. Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. Chest. 89:1986;497-503
13. Houde C., Bohn D.J., Freedom R.M., Rabinovitch M. Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators. Br Heart J. 70:1993;461-468
14. Rich S., kaufmann E., Levy S.L. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl j med. 327:1992;76-81
15. Spray T.L., Bridges N.D. Lung transplantation for pediatric pulmonary hypertension. Progress in Pediatric Cardiology. 12:2001;319-325
16. Chapelier A., Vouhé P., Macchiarini P., Lenot B., Cerrina J., Le Roy Ladurie F., et al. Comparative outcome of heart-lung and lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg. 106:1993;299-307
17. Palevsky H.I., Fishman A.P. The management of primary pulmonary hypertension. JAMA. 265:1991;1014-1020
18. Boucek M.M., Faro A., Novick R.J., Bennett L.E., Fiol B., Keck B.M., et al. The registry of the international society of heart and lung transplantation: third official pediatric report-1999. J Heart Lung Transplant. 18:1999;1151-1172
19. Date H., Aoe M., Nagahiro I., Sano Y., Andou A., Matsubara H., et al. Living-donor lobar lung transplantation for various lung diseases. J Thorac Cardiovasc Surg. 126:2003;476-481
20. Fuster V., Steele P.M., Edwards W.D., Gersh B.J., McGoon M.D., Frye R.L. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 70:1984;580-587
21. McLaughlin V.V., Genthner D.E., Panella M.M., Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 338:1998;273-277
22. Barst R.J., Rubin L.J., Long W.A., McGoon M.D., Rich S., Badesh D.B., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy in primary pulmonary hypertension. N Engl J Med. 334:1996;296-302. The primary Pulmonary Hypertension Study Group
23. Barst R.J., McGoon M., McLaughin V., Tapson V., Rich S., Rubin L., et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 41:2003;2119-2125
24. Giaid A., Yanagisawa M., Langleben D., Michel R.P., Levy R., Shennib H., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 328:1993;1732-1739
25. Channick R.N., Simonneau G., Sitbon O., Robbins I.M., Frost A., Tapson V.F., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 358:2001;1119-1123
26. Rubin L.J., Badesch D.B., Barst R.J., Galié N., Black C.M., Keogh A., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 346:2002;896-903
27. Barst R.J., Ivy D., Dingemanse J., Widlitz A., Schmitt K., Doran A., et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 73:2003;372-382
28. Weimann J., Ullrich R., Hromi J., Fujino Y., Clark M.W., Bloch K.D., et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology. 92:2000;1702-1712
29. Michelakis E., Tymchak W., Lien D., Webster L., Hashimoto K., Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 105:2002;2398-2403
30. Ghofrani H.A., Wiedemann R., Rose F., Shermuly R.T., Olschewski H., Weissmann N., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet. 360:2002;895-900
31. Ghofrani H.A., Rose F., Schermuly R.T., Olschewski H., Wiedemann R., Kreckel A. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 42:2003;158-164
32. Atz A.M., Wessel D.L. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology. 91:1999;307-310
33. ®) per os en cas d'hypertension artérielle pulmonaire après chirurgie cardiaque pédiatrique. Ann Fr Anesth et Réanim. 22:2003;140-143
34. Schulze-Neick I., Hartenstein P., Li J., Stiller B., Nagdyman N., Hübler P., et al. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation. 108:(suppl 1):2003;II-167-II-173
35. Cowan K.N., Heilbut A., Humpl T., Lam C., Ito S., Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med. 6:2000;698-702
36. Campbell A.I., Kuliszewski M.A., Stewart D.J. Cell-based gene transfer to the pulmonary vasculature: endothelial nitric oxide synthase overexpression inhibits monocrotaline-induced pulmonary hypertension. Am J Respir Cell Mol Biol. 21:1999;567-575
37. Nabel E.G. New approaches to pulmonary hypertension: will therapies in mice work in humans? Circulation. 101:2000;839-840
38. Batista R.J., Santos J.L., Takeshita N., Eocchino L., Lima P.L., Goehr M., et al. Successful reversal of pulmonary hypertension in Eisenmenger complex. Arq Bras Cardiol. 68:(4):1997;279-280
39. Sadr I.M., Tan P.E., Kieran W.W., Jenkins K.J. Mechanism of pulmonary vein stenosis in infants with normally connected veins. Am J Cardiol. 86:2000;577-579
40. Rozkovec A., Montanes P., Oakley C.M. Factors that influence the outcome of primary pulmonary hypertension. Br Heart J. 55:1986;449-458
41. Sandoval J., Gaspar J., Pulido T., Bautista E., Martinez-Guerra M.L., Zeballos M., et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol. 32:1998;297-304
42. Rich S., Dodin E., McLaughlin V.V. Usefulness of atrial septostomy as a treatment for primary pulmonary hypertension and guidelines for its application. Am J cardiol. 80:1997;369-371